Platelets from HIV-infected individuals on antiretroviral drug therapy with poor CD4+ T cell recovery can harbor replication-competent HIV despite viral suppression.
Fernando RealClaude CapronAlexis SennepinRiccardo ArrigucciAiwei ZhuGérémy SannierJonathan ZhengLin XuJean-Marc MasséSégolène GreffeMichelle CazabatMaribel DonosoPierre DelobelJacques IzopetEliseo A EugeninMaria Laura GennaroElisabeth RouveixElisabeth Cramer BordéMorgane BomselPublished in: Science translational medicine (2021)
In addition to hemostasis, human platelets have several immune functions and interact with infectious pathogens including HIV in vitro. Here, we report that platelets from HIV-infected individuals on combined antiretroviral drug therapy (ART) with low blood CD4+ T cell counts (<350 cells/μl) contained replication-competent HIV despite viral suppression. In vitro, human platelets harboring HIV propagated the virus to macrophages, a process that could be prevented with the biologic abciximab, an anti-integrin αIIb/β3 Fab. Furthermore, in our cohort, 88% of HIV-infected individuals on ART with viral suppression and with platelets containing HIV were poor immunological responders with CD4+ T cell counts remaining below <350 cells/μl for more than one year. Our study suggests that platelets may be transient carriers of HIV and may provide an alternative pathway for HIV dissemination in HIV-infected individuals on ART with viral suppression and poor CD4+ T cell recovery.
Keyphrases
- hiv infected
- antiretroviral therapy
- human immunodeficiency virus
- hiv positive
- hiv infected patients
- hiv aids
- sars cov
- endothelial cells
- induced apoptosis
- hepatitis c virus
- oxidative stress
- cell cycle arrest
- emergency department
- subarachnoid hemorrhage
- bone marrow
- peripheral blood
- south africa
- blood brain barrier
- drug induced
- antimicrobial resistance
- replacement therapy